- Email: [email protected]
Erratum to “The α3 and β4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice”
Neuropharmacology 47 (2004) 1113–1113 www.elsevier.com/locate/neuropharm
Erratum
Erratum to ‘‘The a3 and b4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice’’ Neuropharmacology 47 (2004) 401–4075 Ramiro Salas, Kimberley D. Cook, Laura Bassetto, Mariella DeBiasi Division of Neuroscience, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
The publisher regrets that Fig. 1 was incorrectly reproduced in the above published article. The correct version of Fig. 1 and caption are printed below.
Fig. 1. Nicotine-induced seizures and hypolocomotion in b4N6 +/+ and b4N6 / mice, and in a3mix +/+ and a3mix +/ mice. (A) Dose response curves for the convulsant effects of nicotine in b4N6 +/+ and b4N6 / mice. Each data point shows the percentage of mice that received a score of four (seized) or five (seized and died) when treated with nicotine; (B) reduced effect of nicotine on the open field in b4N6 / mice. The total distance traveled by mice in an open field was measured for 5 min immediately after i.p. injection of 0.5 mg/kg nicotine or PBS. Averages SEM are shown. #p< 0:05 compared to b4N6 +/+ mice injected with PBS (ANOVA); (C) dose response curves for the convulsant effects of nicotine in a3mix +/+ and a3mix +/ mice. Each data point shows the percentage of mice that received a score of four (seized) or five (seized and died) when treated with nicotine. p< 0:05, p< 0:0001 (Fisher exact test); (D) effect of nicotine in the open field in a3mix +/+ and a3mix +/ mice. The total distance traveled by mice in an open field was measured for 5 min immediately after injection of 0.5 mg/kg nicotine or PBS. Averages SEM are shown. #p< 0:05 compared to PBS controls (ANOVA).
5
PII of original article doi: 10.1016/j.neuropharm.2004.05.002 Corresponding author. Tel.: +1-713-798-3618; fax: +1-713-7983946. E-mail address: [email protected] (M. DeBiasi).
0028-3908/$ - see front matter # 2004 Elsevier Ltd. All rights reserved. doi:10.1016/j.neuropharm.2004.08.005
Erratum
Erratum to ‘‘The a3 and b4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice’’ Neuropharmacology 47 (2004) 401–4075 Ramiro Salas, Kimberley D. Cook, Laura Bassetto, Mariella DeBiasi Division of Neuroscience, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
The publisher regrets that Fig. 1 was incorrectly reproduced in the above published article. The correct version of Fig. 1 and caption are printed below.
Fig. 1. Nicotine-induced seizures and hypolocomotion in b4N6 +/+ and b4N6 / mice, and in a3mix +/+ and a3mix +/ mice. (A) Dose response curves for the convulsant effects of nicotine in b4N6 +/+ and b4N6 / mice. Each data point shows the percentage of mice that received a score of four (seized) or five (seized and died) when treated with nicotine; (B) reduced effect of nicotine on the open field in b4N6 / mice. The total distance traveled by mice in an open field was measured for 5 min immediately after i.p. injection of 0.5 mg/kg nicotine or PBS. Averages SEM are shown. #p< 0:05 compared to b4N6 +/+ mice injected with PBS (ANOVA); (C) dose response curves for the convulsant effects of nicotine in a3mix +/+ and a3mix +/ mice. Each data point shows the percentage of mice that received a score of four (seized) or five (seized and died) when treated with nicotine. p< 0:05, p< 0:0001 (Fisher exact test); (D) effect of nicotine in the open field in a3mix +/+ and a3mix +/ mice. The total distance traveled by mice in an open field was measured for 5 min immediately after injection of 0.5 mg/kg nicotine or PBS. Averages SEM are shown. #p< 0:05 compared to PBS controls (ANOVA).
5
PII of original article doi: 10.1016/j.neuropharm.2004.05.002 Corresponding author. Tel.: +1-713-798-3618; fax: +1-713-7983946. E-mail address: [email protected] (M. DeBiasi).
0028-3908/$ - see front matter # 2004 Elsevier Ltd. All rights reserved. doi:10.1016/j.neuropharm.2004.08.005